News articles about Zogenix (NASDAQ:ZGNX) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zogenix earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.3421593414635 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media headlines that may have effected Accern’s analysis:

ZGNX has been the topic of a number of recent analyst reports. ValuEngine raised Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Zacks Investment Research lowered Zogenix from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. BidaskClub lowered Zogenix from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. Mizuho reissued a “buy” rating and set a $51.00 target price (up from $28.00) on shares of Zogenix in a report on Friday, September 29th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $26.00 target price on shares of Zogenix in a report on Monday, June 26th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $40.00.

Zogenix (NASDAQ:ZGNX) opened at 38.30 on Friday. The company’s 50 day moving average price is $17.73 and its 200-day moving average price is $13.83. Zogenix has a 12-month low of $7.50 and a 12-month high of $41.65. The firm’s market capitalization is $951.41 million.

Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.01). The business had revenue of $7.10 million for the quarter, compared to analysts’ expectations of $3.48 million. Zogenix had a negative net margin of 309.76% and a negative return on equity of 70.75%. The business’s revenue was up 238.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.76) earnings per share. On average, equities analysts anticipate that Zogenix will post ($3.62) earnings per share for the current fiscal year.

In other news, major shareholder Life Sciences Maste Perceptive bought 300,000 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The stock was acquired at an average cost of $37.50 per share, with a total value of $11,250,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/07/zogenix-zgnx-given-media-sentiment-rating-of-0-18.html.

About Zogenix

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Insider Buying and Selling by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Stock Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related stocks with our FREE daily email newsletter.